By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on Clinical Research is the subject of a report. According to news reporting from Hokkaido, Japan, by NewsRx journalists, research stated, "Antiangiogenesis has been the focus of a new strategy for the treatment of obesity. However, little is known regarding the issue of whether targeting angiogenesis by nanoparticle-targeted therapeutic is advantageous or not in debugging the co-morbidity associated with diet-induced obesity (DIO) and the metabolic syndrome."
The news correspondents obtained a quote from the research from Hokkaido University, "We report herein on the positive effect of prohibitin (an adipose vascular marker)-targeted nanoparticle (PTNP) encapsulated in a proapoptotic peptide [(D)(KLAKLAK)(2), KLA] on DIO and dysfunctional adipose tissue, a major mediator of the metabolic syndrome, as evidenced by ectopic fat deposition. The systemic injection of DIO mice with a low dose of KLA-PTNP, rather than a bioconjugate composed of the same targeting peptide and KLA (Adipotide) resulted in a reduction in body weight, as evidenced by a significant decrease in serum leptin levels, in parallel with an antiobesity effect on dysfunctional adipose cells, including adipocytes and macrophages. In addition, the KLA-PTNP treatment resulted in a reduction in ectopic fat deposits in liver and muscle with the lipolytic action of elevated serum adiponectin, with no detectable hepatoxicity. Notably, drug delivery via PTNP that had accumulated in obese fat via the enhanced permeability and retention effect was enhanced by multivalent active targeting and cytoplasmic delivery into adipose endothelial cells via escaping from endosomes/lysosomes."
According to the news reporters, the research concluded: "Thus, vascular-targeted nanotherapy has the potential to contribute to the control of adipose function and ectopic fat deposition associated with obesity and the metabolic syndrome."
For more information on this research see: A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. Journal of Controlled Release, 2013;171(2):104-112. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news journalists report that additional information may be obtained by contacting M.N. Hossen, Hokkaido University, Fac Pharmaceut Sci, Lab Mol Design Pharmaceut, Kita Ku, Sapporo, Hokkaido 0600812, Japan. Additional authors for this research include K. Kajimoto, H. Akita, M. Hyodo and H. Harashima (see also Clinical Research).
Keywords for this news article include: Asia, Japan, Obesity, Hokkaido, Treatment, Bariatrics, Healthcare, Overnutrition, Clinical Research, Diet and Nutrition, Metabolic Syndrome, Nutrition Disorders, Diseases and Conditions, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC